MellinghoffIKvan den BentMJBlumenthalDT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med2023; 389: 589-601.
2.
SharmaNMallelaANShiDD, et al. Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials. Neurooncol Adv2023; 5: vdad053.
3.
OstromQKruchkoCNeffC, et al. The Central Brain Tumor Registry of the United States Histopathological Grouping Scheme provides clinically relevant brain and other central nervous system categories for cancer registry data. J Registry Manag2022; 49: 139-152.
4.
PertzMSchlömerSSeidelC, et al. Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up. J Neurooncol2023; 164: 353-366.
5.
GiovagnoliARMenesesRFPaterliniC, et al. Cognitive awareness after treatment for high-grade glioma. Clin Neurol Neurosurg2021; 210: 106953.
6.
MellinghoffIKPenas-PradoMPetersKB, et al. Vorasidenib, a dual inhibitor of mutant idh1/2, in recurrent or progressive glioma: Results of a first-in-human phase I trial. Clin Cancer Res2021; 27: 4491-4499.
7.
SilvaniA. New perspectives: Glioma in adult patients. Tumori2023; 109: 350-355.
